A 24-week, parallel-group, open-label, randomized clinical trial comparing the early antiviral efficacy of telbivudine and entecavir in the treatment of hepatitis B e antigen-positive chronic hepatitis B virus infection in adult Chinese patients
- 1 April 2010
- journal article
- research article
- Published by Elsevier in Clinical Therapeutics
- Vol. 32 (4) , 649-658
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Chronic hepatitis B: early viral suppression and long‐term outcomes of therapy with oral nucleos(t)idesJournal of Viral Hepatitis, 2009
- Early hepatitis B virus DNA reduction in hepatitis B e antigen–positive patients with chronic hepatitis BHepatology, 2008
- Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trialHepatology, 2008
- Telbivudine for the management of chronic hepatitis B virus infectionClinical Therapeutics, 2007
- Initial viral response is the most powerful predictor of the emergence of YMDD mutant virus in chronic hepatitis B patients treated with lamivudineHepatology Research, 2007
- Entecavir is a potent anti-HBV drug superior to lamivudine: experience from clinical trials in ChinaJournal of Antimicrobial Chemotherapy, 2007
- Two-Year Assessment of Entecavir Resistance in Lamivudine-Refractory Hepatitis B Virus Patients Reveals Different Clinical Outcomes Depending on the Resistance Substitutions PresentAntimicrobial Agents and Chemotherapy, 2007
- Chronic hepatitis BHepatology, 2007
- Predicting Cirrhosis Risk Based on the Level of Circulating Hepatitis B Viral LoadGastroenterology, 2006
- Standardization of clinical enzyme assays: a reference method for aspartate and alanine transaminases.Journal of Clinical Pathology, 1972